We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.34B
AUM Growth
+$16.4M
Cap. Flow
-$1.65M
Cap. Flow %
-0.12%
Top 10 Hldgs %
51.3%
Holding
73
New
15
Increased
18
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$54.1M
2
BSX icon
Boston Scientific
BSX
+$40.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$40.2M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$34.8M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$22.4M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$49M
2
CMRX
Chimerix, Inc.
CMRX
+$40.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.8M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$33.8M
5
INCY icon
Incyte
INCY
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Miscellaneous 9.9%
3 Communication Services 1.56%
4 Industrials 0.57%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
26
DELISTED
NanoString Technologies, Inc.
NSTG
$20M 1.49%
1,357,692
-27,949
-2% -$411K
WVE icon
27
Wave Life Sciences
WVE
$993M
$18.3M 1.37%
+1,213,627
New +$19M
CTMX icon
28
CytomX Therapeutics
CTMX
$699M
$14.4M 1.08%
+738,356
New +$11.7M
HNT
29
DELISTED
HEALTH NET INC
HNT
$12.4M 0.93%
181,029
+1,800
+1% +$115K
ELGX
30
DELISTED
Endologix Inc
ELGX
$9.97M 0.75%
+100,718
New +$10.8M
OXFD
31
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$9.89M 0.74%
860,288
-167,844
-16% -$2.08M
CRL icon
32
Charles River Laboratories
CRL
$13.9B
$9.84M 0.74%
+122,400
New +$8.83M
TRIV
33
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$9.73M 0.73%
1,462,762
-1,221
-0.1% -$8.1K
FATE icon
34
Fate Therapeutics
FATE
$291M
$7.99M 0.6%
2,371,001
+296,165
+14% +$1.24M
PGND
35
DELISTED
PRESS GANEY HOLDINGS INC COM STK (DE)
PGND
$7.56M 0.57%
239,616
+154,650
+182% +$4.93M
BPMC
36
DELISTED
Blueprint Medicines
BPMC
$7.29M 0.55%
276,687
-90,798
-25% -$2.04M
GBT
37
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.07M 0.53%
218,718
-44,174
-17% -$1.91M
DRRX
38
DELISTED
DURECT Corp
DRRX
$5.81M 0.43%
262,842
+1,510
+0.6% +$32.7K
NVTA
39
DELISTED
Invitae Corporation
NVTA
$5.42M 0.41%
660,129
– –
CASC
40
DELISTED
Cascadian Therapeutics, Inc.
CASC
$5.17M 0.39%
388,550
-213,948
-36% -$3.68M
PRQR icon
41
ProQR Therapeutics
PRQR
$323M
$4.84M 0.36%
557,193
-103,623
-16% -$1.19M
PFE icon
42
Pfizer
PFE
$159B
$4M 0.3%
+130,485
New +$4.1M
CARM
43
DELISTED
Carisma Therapeutics
CARM
$2.64M 0.2%
43,793
+1,375
+3% +$78.1K
CFMS
44
DELISTED
Conformis, Inc. Common Stock
CFMS
$2.17M 0.16%
5,028
-22,526
-82% -$11.3M
CELG
45
DELISTED
Celgene Corp
CELG
$1.2M 0.09%
+10,055
New +$1.16M
IHF icon
46
iShares US Healthcare Providers ETF
IHF
$1.23B
$562K 0.04%
+22,600
New +$561K
CCXI
47
DELISTED
ChemoCentryx, Inc.
CCXI
$512K 0.04%
63,189
-437,426
-87% -$3.1M
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$373K 0.03%
620
+160
+35% +$108K
LAB icon
49
Standard BioTools
LAB
$252M
$352K 0.03%
32,561
+7,978
+32% +$78.3K
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$317K 0.02%
4,530
-4,720
-51% -$322K
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2015 Portfolio in Review

As of Q4 2015, Redmile Group held 73 positions worth $1.34B, up 1.2% from $1.32B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Redmile Group's Q4 2015 filing shows 15 new, 18 increased, 22 reduced and 16 closed positions. Its largest new stake was Boston Scientific: 2,251,020 shares worth $41.5M. The largest sale was Rite Aid Corporation, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Communication Services.

  • Redmile Group's largest Q4 2015 buy was Boston Scientific: 2,251,020 shares worth $41.5M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2015, an estimated $54.1M increase.
  • Redmile Group's biggest Q4 2015 reduction was Incyte, cutting an estimated $28.5M.
  • Redmile Group fully exited Rite Aid Corporation in Q4 2015, selling an estimated $49M.
  • Redmile Group's ten largest holdings make up 51% of its $1.34B portfolio in Q4 2015.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2015.
  • Redmile Group's portfolio value rose 1.2% quarter-over-quarter to $1.34B.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.